Drug Trial Radar · NCT06825169
A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR101 in the Treatment of Subjects With Interstitial Lung Disease
Last checked: Nov 19, 2026Latest source record: Feb 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Mar 1, 2025
Primary completion
Mar 1, 2026
Study completion Sep 1, 2028
Sponsor
- Lead sponsor
- Nuwacell Biotechnologies Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The target of this trial is to evaluate the safety, tolerability and preliminary efficacy of NCR101 in the treatment of subjects with interstitial lung disease. The trial contains Single ascending dose(SAD) and Multiple ascending dose(MAD). Subjects will receive at least 1 dose of NCR101.
Conditions
- Interstitial Lung Disease (ILD)
Interventions
NCR101 injectionBiological
Subjects will receive one NCR101 injection in Single Ascending Dose(SAD)and receive 4 NCR101 injections in Multiple Ascending Dose(SAD).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Event(AE) or Serious Adverse Event(SAE)Time frame: 4 weeks after administration of SAD and multiple ascending dose (MAD)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.